Abbott Laboratories and Boehringer Ingelheim’s jointly marketed Mobic saw sharp gains in new users in the days following Pfizer’s April 7 withdrawal of Bextra. Nearly 25 percent of former Bextra ...

Abbott Laboratories reported sales of its NSAID Mobic jumped 176 percent following Merck’s withdrawal of Vioxx from the market and news that studies have linked Celebrex and Bextra to heart risk.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON, June ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. MEMPHIS, Tenn. — An On Your Side ...

Rockville, MD - Mobic (meloxicam, Boehringer Ingelheim Pharmaceuticals) became a top-selling prescription drug for relieving osteoarthritis (OA) and rheumatoid arthritis (RA) pain after Vioxx and ...

Boehringer Ingelheim’s arthritis drug Mobic is facing generic competition from several generic rivals in the USA following the expiry of the patent on the drug earlier this week. Boehringer ...

PRAGUE – In a unique managed care clinical trial, Mobic (meloxicam), designed to relieve the signs and symptoms of osteoarthritis, showed significantly greater "patient success" than other commonly ...